With the rising development of bacterial resistance the search for new medical treatments beyond conventional antimicrobials has become a key aim of public health research. Possible innovative strategies include the inhibition of bacterial virulence. However, consideration must be given to the evolutionary and environmental consequences of such new interventions. Virulence and cooperative social behaviour of the bacterium Pseudomonas aeruginosa rely on the quorum-sensing (QS) controlled production of extracellular products (public goods). Hence QS is an attractive target for anti-virulence interventions. During colonization, non-cooperating (and hence less virulent) P. aeruginosa QS-mutants, benefiting from public goods provided by wild type isolates, naturally increase in frequency providing a relative protection from invasive infection. We hypothesized that inhibition of QS-mediated gene expression removes this growth advantage and selection of less virulent QS-mutants, and maintains the predominance of more virulent QS-wild type bacteria. We addressed this possibility in a placebo-controlled trial investigating the anti-QS properties of azithromycin, a macrolide antibiotic devoid of bactericidal activity on P. aeruginosa, but interfering with QS, in intubated patients colonized by P. aeruginosa. In the absence of azithromycin, non-cooperating (and hence less virulent) lasR (QS)-mutants increased in frequency over time. Azithromycin significantly reduced QS-gene expression measured directly in tracheal aspirates. Concomitantly the advantage of lasR-mutants was lost and virulent wild-type isolates predominated during azithromycin treatment. We confirmed these results in vitro with fitness and invasion experiments. Azithromycin reduced growth rate of the wild-type, but not of the lasR-mutant. Furthermore, the lasR-mutant efficiently invaded wild-type populations in the absence, but not in the presence of azithromycin. These in vivo and in vitro results demonstrate that anti-virulence interventions based on QS-blockade diminish natural selection towards reduced virulence and therefore may increase the prevalence of more virulent genotypes in the Hospital environment. More generally, the impact of intervention on the evolution of virulence of pathogenic bacteria should be assessed.
Trial Registration: ClinicalTrials.gov NCT00610623
With the rising development of antibiotic resistance and rapid spread of nosocomial pathogens, the search for new treatments beyond conventional antibiotics becomes a key aim of public health research. As such, anti-virulence therapies might be alternative antimicrobial strategies. However, consideration must be given to the potential evolutionary and environmental consequences of such interventions. Here we demonstrate a significant evolutionary impact of an anti-virulence intervention. Virulence and cooperative social behaviour of Pseudomonas aeruginosa rely on the quorum-sensing (QS) controlled production of extracellular products. In the absence of a specific intervention, non-cooperating (and hence less virulent) QS-mutants exploit and benefit from products provided by wild type isolates. As a consequence these less virulent mutants increase in frequency and provide a relative protection against infection to a colonized patient. In contrast, when QS-gene expression is reduced by the QS-inhibiting drug azithromycin, this advantage of QS-mutants is lost and virulent isolates predominate both in colonized patients and during in vitro experiments. These results suggest that QS-blockade may increase the prevalence of more virulent QS-responders among colonizing isolates in the hospital environment. More generally, the impact of anti-virulence interventions on the ecology and evolution of virulence of pathogenic bacteria needs to be assessed.
Citation: Köhler T, Perron GG, Buckling A, van Delden C (2010) Quorum Sensing Inhibition Selects for Virulence and Cooperation in Pseudomonas aeruginosa. PLoS Pathog 6(5): e1000883. doi:10.1371/journal.ppat.1000883
Editor: David S. Guttman, University of Toronto, Canada
Received: November 5, 2009; Accepted: March 30, 2010; Published: May 6, 2010
Copyright: © 2010 Köhler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The initial clinical study was financed by Anbics Corporation. Work of our teams was supported by the Swiss National Science Foundation (grants 4049-063239 to TK and CvD, grants 320000-108106 and 320000-120011 to CvD), the Research Fund of the Department of Internal Medicine of the University Hospital Geneva (which receives grants from AstraZeneca Switzerland, Pfizer Switzerland and the Wilsdorf Foundation), and by the European Research Council NERC, Leverhulme Trust and Royal Society (AB), and the Clarendon Fund and Fonds Québécois pour la Recherche sur la Nature et les Technologies (GGP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The funders had no role in the experimental design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Anti-virulence therapies have been recently suggested as alternative strategies to circumvent the growing problem of antibiotic resistance , . In P. aeruginosa inhibition of Quorum-Sensing (QS) seems particularly attractive as QS regulates many virulence determinants of this pathogen . Azithromycin is a widely used macrolide antibiotic without significant bactericidal activity on P. aeruginosa . Recent studies suggest azithromycin might be of benefit against this bacterium because it interferes with the QS-circuit and thereby inhibits the expression of a wide range of extracellular virulence factors . Inhibition of QS is likely to have important evolutionary consequences for P. aeruginosa. Both in vitro and in vivo studies suggest that mutants (QS-cheats) that don't respond to QS (specifically, mutants that are defective in one of the QS-receptors, LasR) can have a selective advantage in the presence of QS-wildtypes , . This has been recently demonstrated during colonization of untreated colonized patients in whom QS-cheats accumulated over time . The most likely explanation for this advantage is that the mutants exploit the wild type public goods, without paying the metabolic cost of their production –; although other direct costs of QS in clinical contexts can't be ruled out –. Regardless of the reasons why QS-mutants have a fitness advantage, this advantage is unlikely to be realised if QS is blocked in wild type bacteria. Azithromycin (or any QS-blocker) will therefore reduce, or remove, selection for less virulent QS-cheats and maintain the predominance of more virulent QS-wild type bacteria.
We tested this hypothesis by following the evolutionary dynamics of QS (lasR) mutants in intubated patients colonised by P. aeruginosa, during a placebo controlled clinical trial evaluating the prevention of pneumonia by azithromycin. Whereas the proportion of lasR mutants rapidly increased in the untreated control patients, the proportion did not change in the azithromycin-treated patients. This fitness advantage in the absence, but not the presence, of azithromycin was similarly observed in vitro. More generally, the impact of intervention on the evolution of virulence of pathogenic bacteria should be assessed .
We tested the hypothesis that azithromycin reduces selection for QS-cheats by following prospectively 92 intubated patients (colonization times of three to twenty days), colonized by P. aeruginosa and hospitalized in intensive care units of seventeen European Hospitals, participating in a placebo controlled azithromycin pneumonia prevention trial (see material and methods). Importantly, antibiotic treatments active against P. aeruginosa were forbidden during the trial. We collected a single P. aeruginosa isolate per patient per day from tracheal aspirates and estimated total density of P. aeruginosa bacteria in the aspirates through genomic copy numbers. Adequate microbiological sampling for bacterial population analysis was available for 61 patients (31 placebo and 30 azithromycin) of the initial 92 randomized patients in the intention-to-treat protocol (Figure 1).
Figure 1. Patient enrollment and follow-up.doi:10.1371/journal.ppat.1000883.g001
QS-inhibition in patient
We monitored QS-gene expression directly in tracheal aspirates to document the “in patient” QS-inhibition by azithromycin. Azithromycin significantly reduced the expression of both QS-circuit (lasI; Mann-Whitney test, P = 0.006) as well as QS-target (rhlA; P = 0.005) genes, whereas it did not affect expression of the QS-independent gene trpD (P>0.2) (Figure 2). It is of course possible that azithromycin inhibited the expression of some other genes unrelated to QS. However microarray data have shown that QS-regulated genes were among those whose expression was most severely affected by azithromycin .
Figure 2. In patient QS-inhibition in azithromycin-treated patients.
In patient QS-gene expression was determined as described. Tracheal aspirates from both day −1 and day x with bacterial RNA of adequate quality were available for twelve placebo and eleven azithromycin patients. Expression of QS-circuit gene lasI, QS-target gene rhlA and QS-independent gene trpD measured in tracheal aspirates is shown as the relative value (%) of the last accessible day (Dx) compared to day −1 (set as 100%). A horizontal line indicates the median expression levels. P values were calculated using Mann-Whitney tests.doi:10.1371/journal.ppat.1000883.g002
We determined the evolution of P. aeruginosa QS in patients by first measuring the production of elastase, which is under the control of the lasR QS-system  from the 650 collected isolates (data not shown). Variations in elastase activity correlated with mutations in lasR between independent wild type and mutant lasR alleles (Mann-Whitney: P<0.001), as determined by sequencing this gene in the first isolate obtained from each patient, and then in subsequent isolates presenting a different QS-phenotype (Figure 3). Mutations in lasR were therefore reducing the expression of elastase, and by inference, other lasR-regulated genes. Whereas the proportion of lasR mutants significantly increased through time in the 31 control group patients (Figure 3a; logistic regression: F1,10 = 65.36, P<0.001), there was a small, decline in the proportion of lasR mutants in the 30 azithromycin treated patients (Figure 3a; F1,10 = 32.58, P<0.001; test of whether slopes differ (treatment by time interaction) in full model: F1, 20 = 77.6; P<0.001). In agreement with this observation, isolates from placebo patients showed decreasing mean elastase levels in vitro (Figure 3b; F1,10 = 41.12, P<0.001), while isolates from the azithromycin treated group showed a concomitant increase through time (Figure 3b; F1,10 = 41.12, P<0.001; treatment by time interaction in full model: F1,20 = 26.46, P<0.001).
Figure 3. Evolution of lasR mutants and elastase production in azithromycin-treated and untreated patients.
Change in the proportion of lasR mutants (a) and mean elastase production (b) through time. Solid lines and closed symbols indicate azithromycin-treated patients, and dashed lines and open symbols indicate placebo group. Note that data is presented to day 11 of colonization, despite some samples being collected up to 20 days, because of very small sample sizes (six isolates) by day 12 in the azithromycin-treated group. However, qualitatively identical results were obtained when the whole data set was analysed. The change in the proportion of lasR mutants and elastase through time was analysed using logistic regression, corrected for under-dispersion, and General linear Modelling, respectively in GenStat 10.doi:10.1371/journal.ppat.1000883.g003
These data are consistent with the hypothesis that azithromycin treatment removes any advantage of QS-mutants, because QS is blocked in the wildtype population. There are, however, a number of alternative explanations, particularly as bacterial densities, based on mean P. aeruginosa genomic copy numbers, were twice as large in the placebo compared to the azithromycin group (7×106 and 1.2×107; t = 1.96, P = 0.06). First, azithromycin-imposed reduction in densities could reflect reductions in growth rate, and this could simply have slowed down the rate at which lasR mutants change in frequency. We can however rule this out as a primary explanation for our data, because azithromycin did not only cause a quantitative change in the frequency of lasR mutants, but also a qualitative change: lasR mutants decreased in frequency during azithromycin treatment, whereas they increased in the placebo group (Figure 3). Second, it is possible that azithromycin may reduce selection for lasR mutants if reductions in QS-mediated public goods production results from reductions in bacterial density caused by azithromycin. Third, azithromycin may directly inhibit the growth of lasR mutants more than wildtype bacteria, explaining why there was a small reduction in the frequency of lasR mutants following azithromycin treatment. We address these possibilities below. Furthermore we cannot exclude that azithromycin influenced the structure of the resident bacterial flora of the patients which could in turn influence the P. aeruginosa population and its virulence properties .
QS-inhibition in vitro
To aid the interpretation of the clinical data, we carried out in vitro experiments with wild type P. aeruginosa (PAO1) and an isogenic lasR mutant in the presence and absence of azithromycin. Danesi et al.  measured azithromycin concentrations of 9 mg/kg in lung tissue of patients receiving a comparable dosing regimen as those in our study, hence we used similar concentrations (5 and 10 mg/l) for our in vitro experiments. We first measured growth rates in media where the primary nutrient source is protein (BSA), making lasR-controlled expression of proteases necessary for the production of useable amino acids .
Consistent with previous studies , growth rate of the lasR mutant in monoculture was reduced relative to the wildtype (by approximately 50%) in the absence of azithromycin, demonstrating an advantage of QS in this environment (Figure 4a; 2-sample t-test: P<0.05). The addition of azithromycin reduced densities of both genotypes (linear effect of azithromycin: F1,29 = 71.2, P<0.001), but this reduction was much greater for the wildtype than the lasR mutant (interaction between concentration and genotype: F1,29 = 6.92, P = 0.013), confirming a role of azithromycin in suppressing the production of QS-controlled exoproducts. Given that azithromycin inhibits wildtype growth more than that of the lasR mutant, we are unable to explain the slight drop in the frequency of lasR mutants in the patients.
Figure 4. lasR mutant growth rates and invasion of wild type populations in the presence and absence of azithromycin.
In vitro densities of wildtype (black) and lasR mutant (grey) after 72 hours growth in M9 salts BSA medium (a), and selection coefficients of lasR mutant relative to wildtype (b) as a function of azithromycin (AZM). Bars show means (± SEM) of six replicates. All differences (wildtype versus lasR) in the presence of azithromycin are statistically significant (p<0.05).doi:10.1371/journal.ppat.1000883.g004
We next measured the fitness of the lasR mutant invading wildtype populations (1:100 ratio). Consistent with the in vivo results, we found that the fitness advantage of lasR mutants was decreased with increasing azithromycin concentration (Figure 4b; Linear effect of azithromycin concentration of fitness of lasR mutant: F1,16 = 48.41, P<0.001). Unlike in the clinical context, the lasR mutant still had a slight fitness advantage over the wildtype at the highest concentration of azithromycin used (10 mg/l), suggesting, unsurprisingly, that additional variables influence the fitness of lasR mutants in vivo. These results strongly suggest that the major advantage of lasR mutants in vitro (and presumably in vivo) is their ability to exploit wildtype public goods , and that azithromycin removes this advantage because less public good (elastase) is produced. However, the data do not distinguish between azithromycin directly inhibiting elastase production, or indirectly through density reductions, or both.
We have shown that azithromycin treatment can prevent selection for lasR mutants, and consequently increase the proportion of wild type P. aeruginosa in colonized patients. A number of not mutually exclusive factors may help to explain this pattern, but the data suggests that the primary reason is because azithromycin blocks QS. Blocking QS prevents lasR mutants from exploiting the public goods provided by the wildtype, and reduces any direct costs associated with QS, such as production of extracellular products that are not of benefit in this particular environment . Both in vitro and in patient data obtained from the clinical trial suggest a key role of QS-dependent virulence for the development of infection (Köhler et al., submitted), and support the general consensus from studies using animal models showing that QS-expression (and public goods production in general) is associated with increased virulence , , –. Azithromycin is therefore likely to be of clinical benefit to a treated patient by inhibiting the QS-dependent virulence during the course of the treatment. However, when treatment is discontinued the patient is at risk of being colonized by highly virulent bacteria, with the potential of late onset infections. Moreover a wider use of such anti-virulence interventions may also increase the prevalence of highly virulent QS-wild type isolates within the hospital. More generally, any intervention that reduces bacterial densities is also likely to result in a reduced selective advantage of less virulent mutants that do not make public goods . The study highlights the need to carefully consider both the short and longer term implications of anti-virulence therapy and other interventions (such as vaccines ) on pathogen virulence.
Materials and Methods
We obtained approval for this study by the “Commission Centrale d'Ethique de la Recherche sur l'Etre Humain des Hôpitaux Universitaire de Genève”. Written informed consent from all patients or their legal representatives was obtained according to legal and ethical considerations.
Patients and clinical collection
This randomized, placebo-controlled, double blind study (ANB 006#2001, ClinicalTrials.gov ID#NCT00610623) was designed to assess the efficacy of azithromycin as a quorum-sensing inhibitor in preventing the occurrence of P. aeruginosa pneumonia in ventilated patients with documented colonization. Twenty-one European centers participated in this trial; eight in France, four in Spain, three in Belgium, three in Poland, two in Serbia and one in Switzerland. We screened mechanically-ventilated patients for respiratory tract colonization by P. aeruginosa every 48 hours. Neutropenic patients and patients treated with immunosuppressive drugs were not eligible. Patients with ongoing P. aeruginosa infection, having received macrolides or antibiotics active against the colonizing P. aeruginosa isolate during the last 14 days were excluded. Patients with proven colonization by P. aeruginosa were randomized (D-1) and received either placebo or 300 mg per day iv azithromycin in a double blind fashion for a maximum of 20 days (D1 to Dx). During the study, only the administration of antibiotics inactive against P. aeruginosa was allowed. Detailed information on study design is available in supporting information Protocol S1 and Checklist S1. Patient characteristics and clinical outcome of the study are published elsewhere (van Delden et al., submitted). Starting the first day of proven colonization (D-1), we collected tracheal aspirates (0.3 to 5 ml) and one P. aeruginoa isolate (collection period: 3–20 days) at 24 hours intervals. Samples were frozen at −80°C on site within 15 minutes, and sent on dry ice to the reference research laboratory at the University Hospital Geneva, where all analyses were performed in a blind fashion. The logit-transformed proportion of patients whose isolate was a lasR mutant was analyzed by logistic regression, with time (a covariate), treatment (placebo or azithromycin) and the interaction fitted in GenStat v10. Data were over dispersed, so a scaling factor to equalize the residual error and degrees of freedom was employed.
In patient gene expression analysis
From prospectively collected tracheal aspirates we extracted total genomic DNA and total RNA (for details see supporting information Text S1). We detected (>104 genomic copies/g aspirate) P. aeruginosa DNA in 98% of the aspirates, confirming the colonization by this organism. In the RNA extractions, we detected expression (>5×104 copies/g aspirate) of the rpsL housekeeping gene in 80% of the aspirates. This indicates that quality of both sample handling and RNA extractions were sufficient to detect bacterial gene expression in the majority of the tracheal aspirates. As a second control for the quality of the RNA extracts from clinical samples we plotted the amount of P. aeruginosa bacteria as determined by qRT-PCR from the genomic DNA extractions against the expression of the rpsL housekeeping gene. We observed a good correlation between these two variables (r = 0.69, P<0.001).
Determination of bacterial loads
The number of P. aeruginosa in aspirates was determined by qRT-PCR of genomic DNA preparations. Aliquots of genomic DNA preparations were diluted 10 fold into H2O and 3 µl of this dilution were added to the PCR reaction mix containing 1× Quantitect Sybr Green Master Mix and 600 nM primers in a total volume of 15 µl. PCR conditions were as described below for cDNA analysis. A standard curve was obtained by addition of 10-fold dilutions of a P. aeruginosa culture to an aspirate collected from a patient not colonized by this organism. Genomic DNA was then isolated as described above and quantified by qRT-PCR. Under these conditions, we detected 104 CFU/g aspirate. Standard curves yielded reproducible values during the 3-month analysis period. P. aeruginosa was found in the aspirates at levels varying from 4×104–1.8×108 CFU/g.
In vitro experiments
P. aeruginosa strain PAO1 was competed against a rare invading isogenic lasR knockout mutant  in 200 µl M9 minimal salts medium supplemented with 1% BSA  in 96-well plates, shaken at 200 rpm at 37°C in the presence or absence of azithromycin (5 and 10 mg/l) for 72 hours. Six wells per environment were inoculated with 107 cells of overnight cultures (grown in LB medium at 37°C), at a ratio of 1:100 lasR mutant: wild type. Selection coefficients of the lasR mutants was calculated as the differences in malthusian parameters (ln(final density/starting density) as previously described , with cell counts determined by plating on LB agar and LB supplemented with 50 mg/l tetracycline. A selection coefficient of zero indicates that strains have equal fitness. Selection coefficients were regressed against azithromycin concentration. Densities (colony forming units) of pure cultures (6 replicates per treatment) under the same conditions were determined at the same time. Densities were log10-transformed, to meet assumption of general linear models, and concentration (a covariate), strain and the interaction fitted in GenStat.
Supplementary material and methods
(0.03 MB DOC)
(0.36 MB PDF)
(0.06 MB DOC)
Conceived and designed the experiments: TK AB CvD. Performed the experiments: TK GGP. Analyzed the data: TK GGP AB CvD. Wrote the paper: TK AB CvD.
- 1. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, et al. (2003) Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 22: 3803–3815.
- 2. Bjarnsholt T, Givskov M (2007) Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 362: 1213–1222.
- 3. Van Delden C, Iglewski BH (1998) Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg Infect Dis 4: 551–560.
- 4. Molinari G, Guzman CA, Pesce A, Schito GC (1993) Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 31: 681–688.
- 5. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, et al. (2001) Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45: 1930–1933.
- 6. Diggle SP, Griffin AS, Campbell GS, West SA (2007) Cooperation and conflict in quorum-sensing bacterial populations. Nature 450: 411–414.
- 7. Sandoz KM, Mitzimberg SM, Schuster M (2007) Social cheating in Pseudomonas aeruginosa quorum sensing. Proc Natl Acad Sci U S A 104: 15876–15881.
- 8. Köhler T, Buckling A, Van Delden C (2009) Cooperation and virulence of clinical Pseudomonas aeruginosa populations. Proc Natl Acad Sci U S A 106: 6339–6344.
- 9. Brown SP, Hochberg ME, Grenfell BT (2002) Does multiple infection select for raised virulence? Trends Microbiol 10: 401–405.
- 10. West SA, Buckling A (2003) Cooperation, virulence and siderophore production in bacterial parasites. Proc Biol Sci 270: 37–44.
- 11. Buckling A, Brockhurst MA (2008) Kin selection and the evolution of virulence. Heredity 100: 484–488.
- 12. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103: 8487–8492.
- 13. D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Deziel E, et al. (2007) Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 64: 512–533.
- 14. Heurlier K, Denervaud V, Haenni M, Guy L, Krishnapillai V, et al. (2005) Quorum-sensing-negative (lasR) mutants of Pseudomonas aeruginosa avoid cell lysis and death. J Bacteriol 187: 4875–4883.
- 15. Gandon S, Mackinnon MJ, Nee S, Read AF (2001) Imperfect vaccines and the evolution of pathogen virulence. Nature 414: 751–756.
- 16. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, et al. (2006) Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 50: 1680–1688.
- 17. Pearson JP, Pesci EC, Iglewski BH (1997) Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J Bacteriol 179: 5756–5767.
- 18. Duan K, Dammel C, Stein J, Rabin H, Surette MG (2003) Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 50: 1477–1491.
- 19. Danesi R, Lupetti A, Barbara C, Ghelardi E, Chella A, et al. (2003) Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 51: 939–945.
- 20. Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, et al. (2008) Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 14: 337–343.
- 21. Smith RS, Iglewski BH (2003) P. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol 6: 56–60.
- 22. Rumbaugh KP, Diggle SP, Watters CM, Ross-Gillespie A, Griffin AS, et al. (2009) Quorum sensing and the social evolution of bacterial virulence. Curr Biol 19: 341–345.
- 23. Harrison EF, Browning L, Vos M, Buckling A (2006) Cooperation and virulence in acute Pseudomonas aeruginosa infections. BMC Biology 4: 21.
- 24. Brown SP, Johnstone RA (2001) Cooperation in the dark: signalling and collective action in quorum-sensing bacteria. Proc Biol Sci 268: 961–965.
- 25. Köhler T, Kocjancic-Curty L, Barja F, Van Delden C, Pechère JC (2000) Swarming of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J Bacteriol 182: 5990–5996.
- 26. Lenski RE, Rose MR, Simpson SC, Tadler SC (1991) Long term experimental evolution in Escherichia coli. 1. Adaptation and divergence during 2000 generations. Am Nat 138: 1315–1341.